Loic Guillevin

Summary

Country: France

Publications

  1. ncbi request reprint Management of virus-induced systemic vasculitides
    Loic Guillevin
    Department of Internal Medicine, Hopital Avicenne, AP HP, Universite Paris Nord, 125 rue de Stalingrad, 93009 Bobigny Cedex, France
    Curr Rheumatol Rep 4:60-6. 2002
  2. ncbi request reprint Indications of plasma exchanges for systemic vasculitides
    Loic Guillevin
    Department of Internal Medicine, Hopital Avicenne, Universite Paris Nord, Assistance Publique Hopitaux de Paris, Bobigny, France
    Ther Apher Dial 7:155-60. 2003
  3. ncbi request reprint Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients
    Loic Guillevin
    Hopital Avicenne, Assistance Publique Hopitaux de Paris, Universite Paris Nord, Bobigny, France
    Arthritis Rheum 49:93-100. 2003
  4. ncbi request reprint [Systemic necrotizing vasculitides: classifications and therapeutic strategies]
    L Guillevin
    Service de Medecine Interne, Hopital Avicenne, Universite Paris Nord, 125, rue de Stalingrad, 93000, Bobigny, France
    Rev Med Interne 24:172-82. 2003
  5. ncbi request reprint Therapeutic strategies for systemic necrotizing vasculitides
    Loic Guillevin
    Department of Internal Medicine, Hopital Cochin, Assistance Publique Hopitaux de Paris, université Paris René Descartes, Paris, France
    Allergol Int 56:105-11. 2007
  6. doi request reprint Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database
    Christian Pagnoux
    Universite Paris Descartes, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    Arthritis Rheum 62:616-26. 2010
  7. ncbi request reprint Analysis of autoantibody repertoires in small- and medium-sized vessels vasculitides. Evidence for specific perturbations in polyarteritis nodosa, microscopic polyangiitis, Churg-Strauss syndrome and Wegener's granulomatosis
    Youri Chanseaud
    UPRES EA 3408, Formation Associee Claude Bernard, UFR SMBH Leonard de Vinci, Bobigny, France
    J Autoimmun 24:169-79. 2005
  8. ncbi request reprint [Treatment of ANCA-associated vascularitides]
    Loic Guillevin
    Service de Medecine Interne, Centre de référence national, Plan maladies rares, vascularites et sclérodermie systémique, Hopital Cochin, AP HP, Universite Paris 5 Rene Descartes, Paris, France
    Presse Med 36:922-7. 2007
  9. ncbi request reprint Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients
    Camillo Ribi
    Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, Paris, France
    Arthritis Rheum 58:586-94. 2008
  10. doi request reprint Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors
    Maxime Samson
    Service de Medecine Interne, Centre National de Référence Vascularites Nécrosantes et Sclérodermie Systémique, Hopital Cochin, AP HP, Universite Paris Descartes, Inserm U 1060, Paris, France Service de Médecine Interne et Immunologie Clinique, Hopital du Bocage, Dijon, France
    Autoimmun Rev 13:197-205. 2014

Collaborators

Detail Information

Publications91

  1. ncbi request reprint Management of virus-induced systemic vasculitides
    Loic Guillevin
    Department of Internal Medicine, Hopital Avicenne, AP HP, Universite Paris Nord, 125 rue de Stalingrad, 93009 Bobigny Cedex, France
    Curr Rheumatol Rep 4:60-6. 2002
    ..Relapses are frequent...
  2. ncbi request reprint Indications of plasma exchanges for systemic vasculitides
    Loic Guillevin
    Department of Internal Medicine, Hopital Avicenne, Universite Paris Nord, Assistance Publique Hopitaux de Paris, Bobigny, France
    Ther Apher Dial 7:155-60. 2003
    ..We review herein these indications of plasma exchanges in the light of the results of major trials...
  3. ncbi request reprint Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients
    Loic Guillevin
    Hopital Avicenne, Assistance Publique Hopitaux de Paris, Universite Paris Nord, Bobigny, France
    Arthritis Rheum 49:93-100. 2003
    ....
  4. ncbi request reprint [Systemic necrotizing vasculitides: classifications and therapeutic strategies]
    L Guillevin
    Service de Medecine Interne, Hopital Avicenne, Universite Paris Nord, 125, rue de Stalingrad, 93000, Bobigny, France
    Rev Med Interne 24:172-82. 2003
    ..The knowledge of systemic necrotizing vasculitides improved since new classifications have been established along with a better understanding of pathogenesis of the diseases. The major vasculitides are described herein...
  5. ncbi request reprint Therapeutic strategies for systemic necrotizing vasculitides
    Loic Guillevin
    Department of Internal Medicine, Hopital Cochin, Assistance Publique Hopitaux de Paris, université Paris René Descartes, Paris, France
    Allergol Int 56:105-11. 2007
    ..Some of them have achieved promising positive effects, for example, anti-CD20 monoclonal antibodies, and are now being evaluated in prospective trials...
  6. doi request reprint Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database
    Christian Pagnoux
    Universite Paris Descartes, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    Arthritis Rheum 62:616-26. 2010
    ..This study was undertaken to describe the main characteristics of and long-term outcomes in patients with well-characterized PAN diagnoses...
  7. ncbi request reprint Analysis of autoantibody repertoires in small- and medium-sized vessels vasculitides. Evidence for specific perturbations in polyarteritis nodosa, microscopic polyangiitis, Churg-Strauss syndrome and Wegener's granulomatosis
    Youri Chanseaud
    UPRES EA 3408, Formation Associee Claude Bernard, UFR SMBH Leonard de Vinci, Bobigny, France
    J Autoimmun 24:169-79. 2005
    ..These results provide evidence for the specificity of autoantibody repertoires from patients with PAN, WG, CSS and MPA...
  8. ncbi request reprint [Treatment of ANCA-associated vascularitides]
    Loic Guillevin
    Service de Medecine Interne, Centre de référence national, Plan maladies rares, vascularites et sclérodermie systémique, Hopital Cochin, AP HP, Universite Paris 5 Rene Descartes, Paris, France
    Presse Med 36:922-7. 2007
    ..These biologics must be prescribed extremely cautiously and only in trial settings, especially in view of the adverse effects, few but severe, recently been reported with them...
  9. ncbi request reprint Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients
    Camillo Ribi
    Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, Paris, France
    Arthritis Rheum 58:586-94. 2008
    ....
  10. doi request reprint Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors
    Maxime Samson
    Service de Medecine Interne, Centre National de Référence Vascularites Nécrosantes et Sclérodermie Systémique, Hopital Cochin, AP HP, Universite Paris Descartes, Inserm U 1060, Paris, France Service de Médecine Interne et Immunologie Clinique, Hopital du Bocage, Dijon, France
    Autoimmun Rev 13:197-205. 2014
    ..However, relapses remained frequent, requiring IS introduction for nearly half of the patients. To lower the frequencies of relapses and sequelae remains a challenge for FFS=0 PAN and MPA patients. ..
  11. ncbi request reprint Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome
    Régis Sablé-Fourtassou
    Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris 5 Rene Descartes, Paris, France
    Ann Intern Med 143:632-8. 2005
    ..Since testing for antineutrophil cytoplasmic antibodies (ANCA) became available for routine evaluation, no large homogeneous cohort of patients with the Churg-Strauss syndrome has been studied...
  12. ncbi request reprint IgM and IgG autoantibodies from microscopic polyangiitis patients but not those with other small- and medium-sized vessel vasculitides recognize multiple endothelial cell antigens
    Youri Chanseaud
    UPRES EA 3408, Formation Associee Claude Bernard, UFR SMBH Leonard de Vinci, Bobigny, France
    Clin Immunol 109:165-78. 2003
    ..Our results provide evidence that IgM and to a lesser degree IgG from MPA patients specifically recognize multiple EC antigens...
  13. ncbi request reprint Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients
    Anne Bourgarit
    Department of Internal Medicine, Hopital Avicenne, UPRES EA 3409 Université Paris XIII, France
    Medicine (Baltimore) 84:323-30. 2005
    ..Cyclophosphamide-induced cytopenia and infection were responsible for 2 deaths. Despite these iatrogenic complications, early deaths were more frequently the consequence of insufficient or inappropriate therapy...
  14. doi request reprint The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France
    Eric Hachulla
    Hopital Claude Huriez, Department of Internal Medicine, National Reference Center for Scleroderma, and University of Lille, Lille, France
    Arthritis Rheum 60:1831-9. 2009
    ..85%. The aim of this observational study was to investigate the incidence of PAH and pulmonary hypertension (PH) during a 3-year followup of patients from the same cohort (the ItinérAIR-Sclérodermie Study)...
  15. doi request reprint Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: A prospective randomized study of one hundred twenty-four patients
    Camillo Ribi
    Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, 75679 Paris, France
    Arthritis Rheum 62:1186-97. 2010
    ....
  16. doi request reprint Azathioprine or methotrexate maintenance for ANCA-associated vasculitis
    Christian Pagnoux
    Universite Paris Descartes, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    N Engl J Med 359:2790-803. 2008
    ..However, azathioprine and methotrexate have not been compared with regard to safety and efficacy...
  17. pmc Association of gender with clinical expression, quality of life, disability, and depression and anxiety in patients with systemic sclerosis
    Christelle Nguyen
    Universite Paris Descartes, Faculté de Médecine Paris Descartes, Pôle de Médecine Interne, Centre de Référence pour les Vascularites Nécrosantes et la Sclérodermie Systémique, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    PLoS ONE 6:e17551. 2011
    ..To assess the association of gender with clinical expression, health-related quality of life (HRQoL), disability, and self-reported symptoms of depression and anxiety in patients with systemic sclerosis (SSc)...
  18. ncbi request reprint Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients
    Pascal Cohen
    Hopital Cochin, Assistance Publique Hopitaux de Paris, Université René Descartes Paris, Recherche Clinique et Thérapeutique, Paris, France
    Arthritis Rheum 57:686-93. 2007
    ..To compare long and short durations of adjunctive cyclophosphamide for the treatment of severe Churg-Strauss syndrome (CSS)...
  19. ncbi request reprint [Psychiatric manifestations of systemic sclerosis]
    Thierry Baubet
    Service de psychopathologie de l enfant, de l Adolescent, et de Psychiatrie Générale, Hopital Avicenne, Assistance Publique Hôpitaux de Paris et Université Paris Nord, 125, route de Stalingrad, 93009 Bobigny
    Ann Med Interne (Paris) 153:237-41. 2002
    ....
  20. ncbi request reprint Population-based prevalence study of Behçet's disease: differences by ethnic origin and low variation by age at immigration
    Alfred Mahr
    Department of Internal Medicine, Universite Paris 5 Rene Descartes, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    Arthritis Rheum 58:3951-9. 2008
    ..To estimate the prevalence of Behçet's disease (BD) in a multiethnic population living in France, with particular focus on disease risk among immigrants...
  21. pmc Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study
    Eric Hachulla
    Department of Internal Medicine, National Reference Center for Scleroderma, Claude Huriez Hospital, University of Lille, 59037 Lille Cedex, France
    Rheumatology (Oxford) 48:304-8. 2009
    ..This longitudinal study investigated survival, risk factors and causes of death in the multicentre ItinérAIR-Sclérodermie cohort of patients with SSc without severe pulmonary fibrosis or severe left heart disease at baseline...
  22. ncbi request reprint [Microscopic polyangiitis]
    Christian Pagnoux
    Service de Medecine Interne, Centre de référence national, Plan maladies rares, vascularites nécrosantes et sclérodermie systémique, Hopital Cochin, AP HP, Universite Paris 5 Rene Descartes, Paris, France
    Presse Med 36:895-901. 2007
    ..Biological therapies are under evaluation. The remission rate is above 80% with these regimens, and the relapse rate is around 30% at 5 years, lower than for Wegener's granulomatosis...
  23. ncbi request reprint Treatment of refractory and/or severe ANCA-associated systemic necrotizing vasculitides
    Loic Guillevin
    Department of Internal Medicine, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris, Paris, France
    Isr Med Assoc J 10:89-91. 2008
    ..Some of them (e.g., anti-tumor necrosis factor-alpha and anti-CD20 monoclonal antibodies) have achieved promising results and are now often used to treat severe cases...
  24. ncbi request reprint Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients
    Alex Kostianovsky
    Department of Internal Medicine, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, Sorbonne Paris Cité, INSERM U1060, Referral Center for Rare Autoimmune Systemic Diseases, Paris, France
    Clin Exp Rheumatol 30:S83-9. 2012
    ..This study was undertaken to evaluate immunogenicity and tolerance of seasonal (SFV) and A/H1N1 flu vaccines (HFV) in AID patients...
  25. pmc Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts
    Christian Pagnoux
    Hopital Cochin, AP HP, UNIVERSITE DE PARIS, Paris, France
    Arthritis Rheum 58:2908-18. 2008
    ..This study was undertaken to evaluate the applicability of those predictors in an independent cohort followed up by the French Vasculitis Study Group...
  26. doi request reprint Sensitivity to change in systemic sclerosis of the McMaster-Toronto Arthritis Patient Preference Disability Questionnaire (MACTAR): shift in patient priorities over time
    Christelle Nguyen
    Paris Descartes University, UPRES EA 4058, Department of Internal Medicine, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Cochin Hospital, Assistance Publique Hopitaux de Paris AP HP, Paris, France
    J Rheumatol 37:359-64. 2010
    ..To assess the sensitivity to change of the McMaster-Toronto Arthritis Patient Preference Disability Questionnaire (MACTAR) in systemic sclerosis (SSc) and a shift in patient priorities over time...
  27. ncbi request reprint Extraocular manifestations of birdshot chorioretinopathy in 118 French patients
    Christian Pagnoux
    Department of Internal Medicine, National referral center for Systemic necrotizing vasculitides and systemic scleroderma, Hopital Cochin, Universite Paris Descartes, Assistance Publique Hopitaux de Paris, 75879 Paris cedex 14, France
    Presse Med 39:e97-e102. 2010
    ..Published studies on birdshot chorioretinopathy (BCR) did not provide definitive information on possibly associated extraocular manifestations...
  28. doi request reprint Differences in patients with systemic sclerosis recruited from associations and tertiary care settings
    Caroline Mestre-Stanislas
    Universite Paris Descartes, Faculte de Medecine, Pôle de Médecine Interne, Centre de Référence pour les Vascularites Nécrosantes et la Sclérodermie Systémique, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    Presse Med 39:e205-9. 2010
    ..To compare patients with systemic sclerosis (SSc) recruited from a patient association or a tertiary care setting...
  29. ncbi request reprint Polyarteritis nodosa and Churg-Strauss angiitis: characteristics and outcome in 38 patients over 65 years
    Luc Mouthon
    Department of Internal Medicine, Hôpital Avicenne and Université Paris Nord, Bobigny, France
    Medicine (Baltimore) 81:27-40. 2002
  30. ncbi request reprint Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients
    Mathilde de Menthon
    Department of Internal Medicine, Hopital Cochin, University Paris Descartes, Paris, France
    Clin Exp Rheumatol 29:S63-71. 2011
    ..To compare efficacy and tolerance of infliximab versus rituximab to treat refractory Wegener's granulomatosis (WG), and clarify their respective indications...
  31. ncbi request reprint [Insulin autoimmune syndrome revealing systemic lupus erythematosus]
    Samir Rouabhia
    Service de Medecine Interne, Hopital Avicienne, CHU, AP HP, Bobigny
    Ann Med Interne (Paris) 154:59-60. 2003
    ..Treatment with high-dose corticosteroids and cyclophosphamide resulted in restoration of euglycemia associated with resolution of circulating anti-insulin antibodies and parallel improvement in clinical and laboratory features of SLE...
  32. doi request reprint Churg-strauss syndrome: clinical symptoms, complementary investigations, prognosis and outcome, and treatment
    Bertrand Dunogué
    Department of Internal Medicine, National Referral Center for Rare Autoimmune and Systemic Diseases including Vasculitis, Scleroderma, Hopital Cochin, Assistance Publique Hopitaux de Paris, France
    Semin Respir Crit Care Med 32:298-309. 2011
    ..Future therapies might reflect these differences more strongly...
  33. doi request reprint Therapeutic options for systemic sclerosis related interstitial lung diseases
    Luc Mouthon
    Universite Paris Descartes, UPRES EA 4058, Pôle de Médecine Interne et Centre de Référence pour les Vascularites Nécrosantes et la Sclérodermie Systémique, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    Respir Med 104:S59-69. 2010
    ..A subgroup of patients with rapidly progressive ILD might benefit from pulsed intravenous cyclophosphamide combined with prednisone 15 mg daily but this remains to be confirmed...
  34. doi request reprint Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients
    Valerie Martinez
    Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, Paris, France
    Arthritis Rheum 58:308-17. 2008
    ....
  35. doi request reprint Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome
    Eric Hachulla
    Department of Internal Medicine, National Reference Center for Scleroderma, Claude Huriez Hospital, University of Lille, France
    Rheumatology (Oxford) 49:940-4. 2010
    ..To describe the history of SSc-associated pulmonary arterial hypertension (SSc-PAH) in patients with New York Heart Association (NYHA) functional class (FC) II dyspnoea at diagnosis...
  36. ncbi request reprint Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients
    Pierre Charles
    Service de Medecine Interne, Institut Mutualiste Montsouris, 42 Boulevard Jourdan, 75014 Paris, France
    Rheumatology (Oxford) 53:532-9. 2014
    ..Our study was undertaken to describe AAV clinical responses to rituximab used for remission-induction and/or maintenance therapy, assess rituximab's safety profile and evaluate French clinical practices...
  37. doi request reprint Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials
    Maxime Samson
    Service de Medecine Interne, Centre National de Référence Vascularites Nécrosantes et Sclérodermie Systémique, Hopital Cochin, AP HP, Universite Paris Descartes, Inserm U 1060, Paris, France
    J Autoimmun 43:60-9. 2013
    ..Relapses are frequent, especially in patients with anti-myeloperoxidase antibodies and baseline eosinophilia <3000/mm(3)...
  38. ncbi request reprint Lymphoma complicating common variable immunodeficiency with granulomatous disease: report of two cases
    Véronique Le Guern
    Department of Internal Medicine, Hopital Avicenne, Assistance Publique Hôpitaux de Paris and Université Paris Nord, Bobigny, France
    Eur J Haematol 71:459-63. 2003
    ..We describe two CVID patients with systemic granulomatosis who developed B-cell lymphomas, one related to Epstein Barr virus infection, 5 and 12 yr after CVID had been diagnosed...
  39. ncbi request reprint New insights into the pathogenesis of systemic sclerosis
    Mathieu C Tamby
    UPRES EA 3408, Formation Associee Claude Bernard, UFR SMBH Leonard de Vinci, Bobigny, France
    Autoimmun Rev 2:152-7. 2003
    ..Their pathogenetic role(s) remains uncertain. However, genetic, environmental and possibly alloreactive factors might also contribute to disease susceptibility...
  40. ncbi request reprint IgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patients
    Paloma Garcia de la Pena-Lefebvre
    UPRES EA 3408, UFR SMBH Leonard de Vinci, Bobigny, France
    Clin Immunol 111:241-51. 2004
    ..Our results indicate that Ab from patients with limited or diffuse SSc with or without anti-topo 1 Ab exhibit specific and mutually exclusive reactivity patterns...
  41. ncbi request reprint Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities
    Olivier Mir
    Unité d Oncologie Médicale, Service de Medecine Interne, Hopital Cochin, GHU Ouest, Assistance Publique Hopitaux de Paris, Paris, France
    Anticancer Drugs 16:1017-21. 2005
    ....
  42. ncbi request reprint Long-term outcome of 37 patients with Wegener's granulomatosis with renal involvement
    Jacques Eric Gottenberg
    Department of Internal Medicine, Nationale referral center for Vasculitides and Scleroderma, Hopital Cochin, AP HP, Universite Paris 5, Paris
    Presse Med 36:771-8. 2007
    ..This prospective study sought to assess the long-term outcome and identify prognostic factors of patients with kidney disease related to Wegener's granulomatosis (WG)...
  43. ncbi request reprint Stress and coping strategies in systemic lupus erythematosus: a review
    Olivier Bricou
    Department of Psychiatry, Hôpital Avicenne AP HP, Paris 13 University, Bobigny, France
    Neuroimmunomodulation 13:283-93. 2006
    ..Despite the limitations of these studies, therapeutic interventions should be proposed to reduce psychological distress, to improve the quality of life and possibly to moderate the evolution of the disease...
  44. ncbi request reprint Pulmonary arterial hypertension in ANCA-associated vasculitis
    David Launay
    Department of Internal Medicine, Claude Huriez Hospital, National Center for Vascular Manifestations of Scleroderma, EA2686, Regional University Hospital, Lille 2 University, Lille, France
    Sarcoidosis Vasc Diffuse Lung Dis 23:223-8. 2006
    ..In the present report, we describe 4 cases of anti-neutrophil cytoplasmic antibodies (ANCA)-related systemic vasculitis (3 with Wegener's granulomatosis and 1 with microscopic polyangiitis) associated with PAH...
  45. ncbi request reprint Microscopic polyangiitis and polyarteritis nodosa: how and when do they start?
    Christian Agard
    Hopital Avicenne, Assistance Publique Hopitaux de Paris, France
    Arthritis Rheum 49:709-15. 2003
    ..To describe initial clinical symptoms attributable to microscopic polyangiitis (MPA) or polyarteritis nodosa (PAN)...
  46. doi request reprint Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls
    Loic Guillevin
    Department of Internal Medicine, Hopital Cochin, Paris Cedex 14, France
    Rheumatology (Oxford) 51:460-7. 2012
    ..This study was undertaken to describe SRC characteristics, prognosis and outcome, and evaluate the responsibility of CSs in its occurrence...
  47. ncbi request reprint Is pulmonary arterial hypertension really a late complication of systemic sclerosis?
    Eric Hachulla
    Department of Internal Medicine, National Reference Center for Scleroderma, Claude Huriez Hospital, University of Lille, 59037 Lille Cedex, France
    Chest 136:1211-9. 2009
    ..PAH is generally considered to be a late complication of limited cutaneous SSc. This study identified and investigated a subset of SSc patients with early-onset PAH...
  48. doi request reprint Wegener's granulomatosis strictly and persistently localized to one organ is rare: assessment of 16 patients from the French Vasculitis Study Group database
    Christian Pagnoux
    Department of Internal Medicine, Hopital Cochin, 75879 Paris cedex 14, France
    J Rheumatol 38:475-8. 2011
    ..To study the frequency and characteristics of patients with Wegener's granulomatosis (WG) strictly and persistently localized to one organ...
  49. ncbi request reprint [Interstitial lung disease in systemic sclerosis]
    Luc Mouthon
    Service de Medecine Interne, Hopital Cochin, Centre de Référence pour les Vascularites et la Sclérodermie Systémique, AP HP, Paris
    Presse Med 35:1943-51. 2006
    ..A subgroup of patients with rapidly progressive ILD might benefit from intravenous cyclophosphamide pulses in association with 15 mg/d prednisone...
  50. ncbi request reprint Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients
    Loic Guillevin
    Department of Internal Medicine, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    Medicine (Baltimore) 84:313-22. 2005
    ..The major cause of death is gastrointestinal tract involvement. Importantly, the frequency of HBV-PAN has decreased in relation to improved blood safety and vaccination campaigns...
  51. ncbi request reprint Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial
    Raphaele Seror
    Department of Internal Medicine, National Referral Center for Necrotizing Vasculitides and Systemic Sclerosis, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, Paris, France
    Ann Rheum Dis 69:2125-30. 2010
    ....
  52. ncbi request reprint [Therapeutic management of systemic sclerosis]
    Luc Mouthon
    Service de Medecine Interne, Hopital Cochin, Centre de Référence pour les Vascularites Nécrosantes et la Sclérodermie Systémique, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, Faculte de Medecine
    Presse Med 35:1975-82. 2006
    ..The efficacy of disease-modifying agents remains limited however, and none has yet demonstrated its ability to improve survival in a prospective randomized trial...
  53. ncbi request reprint Advances in the treatments of systemic vasculitides
    Loic Guillevin
    Service de Medecine Interne, Hopital Cochin, Assistance Publique Hopitaux de Paris, université Paris René Descartes, 27 rue du Faubourg Saint Jacques, Paris, France
    Clin Rev Allergy Immunol 35:72-8. 2008
    ..The strategies that improve patient's outcome are discussed in the light of the prospective trials organized by international research groups...
  54. doi request reprint The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort
    Loic Guillevin
    Department of Internal Medicine, National Referral Center for Rare Systemic and Autoimmune Diseases Vasculitides and Scleroderma, Hopital Cochin, Assistance Publique Hopitaux de Paris, UPRES 4058, Universite Paris Descartes, INSERM 1016, Paris, France loic guillevin cch aphp fr
    Medicine (Baltimore) 90:19-27. 2011
    ..The better WG prognosis for patients with ENT manifestations, even for patients with other visceral involvement, compared with the prognosis for those without ENT manifestations, probably reflects WG phenotype heterogeneity...
  55. ncbi request reprint Indications for biotherapy in systemic vasculitides
    Loic Guillevin
    Department of Internal Medicine, French Vasculitis Study Group, Centre de Référence Vascularites et Sclérodermie, Hopital Cochin, Universite Paris Descartes, Paris, France
    Clin Rev Allergy Immunol 32:85-96. 2007
    ..Results of international ongoing trials will determine whether the agents may also have a place as first-line treatment...
  56. ncbi request reprint Indication for plasma exchange for systemic necrotizing vasculidities
    Loic Guillevin
    Department of Internal Medicine, Referral Center for Rare Diseases, Vasculitis and Scleroderma, Hopital Cochin, AP HP, Université de Paris René Descartes, 27, rue du Faubourg Saint Jacques, Paris, France
    Transfus Apher Sci 36:179-85. 2007
    ..Although PE does not improve survival, their adjunction to corticosteroids and immunosuppressants for patients with alveolar hemorrhage could also limit the severity of this severe manifestation...
  57. ncbi request reprint [Classification of systemic vasculatides]
    Loic Guillevin
    Centre de référence national, Plan maladies rares, vascularites et sclérodermie systémique, Hopital Cochin, AP HP, Universite Paris 5 Rene Descartes, Paris, France
    Presse Med 36:845-53. 2007
    ....
  58. ncbi request reprint Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjögren's syndrome-related neuropathy
    Benjamin Terrier
    Assistance Publique Hopitaux de Paris, Hopital de Bicetre, Le Kremlin Bicetre, France
    Arthritis Rheum 57:1520-9. 2007
    ..To evaluate the clinicobiologic presentation in patients with primary Sjögren's syndrome (SS)-related peripheral neuropathy, the histologic results of neuromuscular biopsy (NMB), and clinical outcome, and to identify prognostic factors...
  59. ncbi request reprint Systemic sclerosis-associated myopathy
    Brigitte Ranque
    Paris Descartes University, Faculty of Medicine Paris Descartes, UPRES EA 4058, Department of Internal Medicine, French National Reference Center for Systemic Sclerosis and Vasculitides, Cochin Hospital, Assistance Publique des Hopitaux de Paris, France
    Ann N Y Acad Sci 1108:268-82. 2007
    ..In contrast, noninflammatory myopathies often result in milder clinical expression but do not respond to immunosuppressive treatment...
  60. ncbi request reprint [Pathogenesis of systemic scleroderma: immunological aspects]
    Luc Mouthon
    Service de Medecine Interne, Hopital Avicenne, Assistance Public, Hopitaux de Paris, et Université Paris Nord, 125, route de Stalingrad, 93009 Bobigny
    Ann Med Interne (Paris) 153:167-78. 2002
    ..These autoantibodies are good prognosis markers but their pathogenic role remains uncertain...
  61. doi request reprint Churg-Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography: a prospective study on 20 patients
    Julien Marmursztejn
    Department of Cardiology, Hopital Cochin, AP HP, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    Rheumatology (Oxford) 52:642-50. 2013
    ..To determine whether the CMRI-MDE detected in CSS patients reflected fibrosis or myocardial inflammation, patients in CSS remission underwent FDG-PET...
  62. doi request reprint Infections in vasculitis
    Loic Guillevin
    Department of Internal Medicine, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, 27, rue du Faubourg Saint Jacques, 75679 Paris cedex, France
    Best Pract Res Clin Rheumatol 27:19-31. 2013
    ..In patients treated with rituximab, CD19 and gammaglobulins should be monitored regularly. Prophylaxis are needed in patients at risk to develop infections...
  63. ncbi request reprint Central nervous system involvement in Wegener granulomatosis
    Raphaele Seror
    Department of Internal Medicine, Hopital Cochin, Universite Rene Descartes Paris 5, Assistance Publique Hopitaux de Paris, Paris, France
    Medicine (Baltimore) 85:54-65. 2006
    ....
  64. ncbi request reprint When should immunosuppressants be prescribed to treat systemic vasculitides?
    Loic Guillevin
    Service de Medecine Interne, Hopital Avicenne, Assistance Publique Hopitaux de Paris, Universite Paris Nord, Bobigny, France
    Intern Med 42:313-7. 2003
    ..The new therapeutic strategies comprise also new immunosuppressants and new immunomodulating agents which could replace or be associated to the "older drugs"...
  65. ncbi request reprint Thiabendazole-induced acute liver failure requiring transplantation and subsequent diagnosis of polyarteritis nodosa
    Matthieu Groh
    Department of Internal Medicine, Hopital Cochin, Referral Center for Rare Autoimmune and Systemic Diseases, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, Paris, France
    Clin Exp Rheumatol 30:S107-9. 2012
    ..His outcome was favourable after second OLT, under steroids, cyclophosphamide pulses and tacrolimus. In retrospect, his initial symptoms and hypereosinophilia were probably attributable to PAN...
  66. doi request reprint Anti-PL7 antisynthetase syndrome under interferon therapy
    Achille Aouba
    Department of Adult Haematology, Necker Enfants Malades Hospital, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, 149, rue de Sevres, 75015 Paris, France
    Joint Bone Spine 78:94-7. 2011
    ....
  67. doi request reprint Mood and anxiety disorders in systemic sclerosis patients
    Thierry Baubet
    Université de Paris 13, Assistance Publique Hopitaux de Paris AP HP, Hopital Avicenne, Service de Psychopathologie, EA 3413, 93009 Bobigny Cedex, France
    Presse Med 40:e111-9. 2011
    ..To assess the prevalence of mood and anxiety disorders in systemic sclerosis (SSc) patients and the association of these disorders with clinical features...
  68. doi request reprint Remittent non-destructive polysynovitis in P-ANCA-positive vasculitis patients with anti-CCP antibodies
    Christian Pagnoux
    Department of Internal Medicine, National Referral Center for Necrotizing Vasculitides and Systemic Sclerosis, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, 27, rue du Faubourg Saint Jacques, 75879 Paris cedex 14, France
    Joint Bone Spine 77:604-7. 2010
    ....
  69. doi request reprint Analysis of Wegener's granulomatosis responses to rituximab: current evidence and therapeutic prospects
    Achille Aouba
    Department of Internal Medicine and the French Vasculitis Study Group, Assistance Publique Hopitaux de Paris, Universite Paris, 5 René Descartes, Hopital Cochin, 27, rue du Faubourg Saint Jacques, 75679, Paris Cedex 14, France
    Clin Rev Allergy Immunol 34:65-73. 2008
    ..This promising biotherapy opens the way for other therapeutic agents targeting B lymphocytes and to improve our understanding of the pathophysiology of ANCA-associated vasculitis...
  70. doi request reprint Patients with systemic inflammatory and autoimmune diseases are at risk of vaccine-preventable illnesses
    Cecile Marchand-Janssen
    Universite Paris Descartes, Faculte de Medecine, INSERM, CIC BT505, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Cochin Saint Vincent De Paul, Pôle de médecine, CIC de vaccinologie Cochin Pasteur, Paris, France
    Rheumatology (Oxford) 50:1099-105. 2011
    ..To evaluate vaccine coverage and humoral immunity to tetanus, diphtheria and poliomyelitis in adults followed for systemic inflammatory and/or autoimmune diseases (SIADs)...
  71. doi request reprint Low influenza vaccination rate among patients with systemic sclerosis
    Luc Mouthon
    Department of Internal Medicine, Cochin Hospital, Paris Cedex 14, France
    Rheumatology (Oxford) 49:600-6. 2010
    ..To evaluate the influenza vaccination rate and factors influencing it in patients with SSc...
  72. ncbi request reprint Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
    Alice Berezne
    Paris Descartes University, Faculty of Medicine, UPRES EA 4058, Department of Internal Medicine and Reference Center for Necrotizing Vasculitides and Systemic Sclerosis, Cochin Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Ann N Y Acad Sci 1110:271-84. 2007
    ..Since only a minority of SSc patients develops severe ILD, we propose that further studies evaluating CYC should focus on the subgroup of SSc patients with worsening ILD...
  73. doi request reprint Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort
    Cloé Comarmond
    Hopital Cochin, AP HP, and Universite Paris Descartes, Paris 5, Paris, France
    Arthritis Rheum 65:270-81. 2013
    ..This study was undertaken to describe the main characteristics of a larger patient cohort and their long-term outcomes...
  74. ncbi request reprint Alveolar haemorrhage in ANCA-associated vasculitides: 80 patients' features and prognostic factors
    Alex Kostianovsky
    Department of Internal Medicine, Hopital Cochin, Assistance Publique, Hopitaux de Paris, Universite Paris Descartes, Paris, France
    Clin Exp Rheumatol 30:S77-82. 2012
    ..Our objective was to determine the prognostic value of AH in this context...
  75. doi request reprint Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides
    Guillaume Le Guenno
    Hopital Cochin, Assistance Publique Hopitaux de Paris, and Université Paris 5, Paris, France
    Arthritis Rheum 63:1435-45. 2011
    ..To assess hemorrhagic cystitis and urinary tract cancer incidence and predictors in cyclophosphamide (CYC)-treated patients with systemic necrotizing vasculitis (SNV)...
  76. ncbi request reprint Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease
    David Launay
    Department of Internal Medicine, National Center for Vascular Manifestations of Scleroderma, Regional University Hospital Claude Huriez Hospital, Lille, France
    J Rheumatol 34:1005-11. 2007
    ..To determine the prevalence and characteristics of moderate to severe pulmonary hypertension (PH) in patients with systemic sclerosis (SSc) with and without interstitial lung disease (ILD)...
  77. doi request reprint Predictors at diagnosis of a first Wegener's granulomatosis relapse after obtaining complete remission
    Carole Pierrot-Deseilligny Despujol
    Department of Internal Medicine, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, 27, Paris, France
    Rheumatology (Oxford) 49:2181-90. 2010
    ..Although in most patients with WG, induction therapy leads to complete remission (CR), the high relapse rate remains a major problem. This study was undertaken to identify potential predictors of these relapses...
  78. ncbi request reprint Natural and disease associated anti-myeloperoxidase (MPO) autoantibodies
    Philippe Guilpain
    Paris Descartes University, Faculty of Medicine, UPRES EA 4058, Department of Internal Medicine, Paris, France
    Autoimmun Rev 7:421-5. 2008
    ..Thus, anti-MPO Abs could play a pathogenic role in vivo by triggering an oxidative burst leading to severe endothelial damages...
  79. ncbi request reprint [New insights into the pathogenesis of ANCA-positive vasculitides]
    Philippe Guilpain
    Service de Medecine Interne, Centre national de références pour les vascularites systémiques et la sclérodermie systémique, Hopital Cochin, AP HP, Universite Paris V, Paris, France
    Presse Med 36:854-9. 2007
    ..A pathogenic role for antiproteinase 3 antibodies has not yet been clearly established in vivo although it is well documented in vitro...
  80. doi request reprint [Treatment of systemic autoimmune and inflammatory diseases with rituximab]
    Guillaume Bussone
    Universite Paris Descartes, Pôle de Médecine Interne, Centre de Référence pour les Vascularites Nécrosantes et la Sclérodermie Systémique, Hopital Cochin, Assistance Publique Hopitaux de Paris, F 75679 Paris cedex 14, France
    Presse Med 38:808-23. 2009
    ..Relapses of the disease are common around six months after rituximab infusion. The response to retreatment with rituximab is usually the same that was obtained after the first course of treatment...
  81. doi request reprint Churg-Strauss syndrome: evidence for disease subtypes?
    Christian Pagnoux
    Department of Internal Medicine, French Vasculitis Study Group, National Referral Center for Necrotizing Vasculitides and Systemic Scleroderma, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, Paris, France
    Curr Opin Rheumatol 22:21-8. 2010
    ..Conversely, physiopathogenetic mechanisms are not completely elucidated and clearly multiple, thereby suggesting the existence of different disease subtypes...
  82. doi request reprint Reporting of corticosteroid use in systemic disease trials: evidence from a systematic review of the potential impact on treatment effect
    Christian Pagnoux
    INSERM U738, Universite Paris Diderot, Hopital Bichat Claude Bernard, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, Paris, France
    Arthritis Care Res (Hoboken) 62:1002-8. 2010
    ..To study how corticosteroid therapy is planned and described in reports of systemic disease trials and estimate the impact of the between-arm difference in corticosteroid dose on treatment effect...
  83. pmc Virus-induced systemic vasculitides: new therapeutic approaches
    Loic Guillevin
    Department of Internal Medicine, Hopital Cochin, AP HP, Universite Rene Descartes Paris V, 27, rue du Faubourg Saint Jacques, Paris, France
    Clin Dev Immunol 11:227-31. 2004
    ..In vasculitis related to HCV-associated cryoglobulinemia, plasma exchanges improve the outcome but the poor effectiveness of antiviral drugs is not able to favor, usually, a definite recovery of the patients and relapses are frequent...
  84. doi request reprint [Periostitis in systemic necrotizing vasculitides: Study of the 4 cases identified among the 1762 patients of the FVSG database and review of the literature]
    Sophie Périchon
    Pôle de Médecine Interne, centre de référence vascularites systémiques nécrosantes et sclérodermie systémique, Hopital Cochin, Universite Paris Descartes, Assistance Publique Hopitaux de Paris, 75879 Paris cedex 14, France
    Presse Med 39:e165-73. 2010
    ..Periostitis (periosteal new bone formation) is a rare manifestation of systemic necrotizing vasculitis...
  85. ncbi request reprint Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study
    Arsene Mekinian
    Service de Medecine Interne, Universite Paris 13, AP HP, Hopital Jean Verdier, Bondy 93140, France
    Rheumatology (Oxford) 51:882-6. 2012
    ..To analyse the efficacy and tolerance of infliximab in refractory Takayasu arteritis (TA)...
  86. ncbi request reprint [Antileukotrienes and Churg-Strauss syndrome]
    Philippe Guilpain
    Service de Medecine Interne, AP HP, Hopital Cochin, Universite Paris V, Paris, France
    Presse Med 36:890-4. 2007
    ..The onset of Churg-Strauss syndrome in patients treated with LTRA usually requires that they stop this treatment. Prescription of LTRA In patients with Churg-Strauss syndrome should be discussed with specialists...
  87. doi request reprint [Pneumococcal infections and vaccination in patients with systemic autoimmune and/or inflammatory diseases]
    Paula Duchet-Niedziolka
    Centre d Investigation Clinique de Vaccinologie Cochin Pasteur, Pôle de médecine, Groupe Hospitalier Cochin Saint Vincent De Paul, Assistance Publique Hopitaux de Paris, Paris Cedex 14, France
    Presse Med 38:243-50. 2009
    ..More immunogenic vaccine strategy should be evaluated in patients with systemic autoimmune and/or inflammatory diseases to provide better vaccine coverage...
  88. ncbi request reprint Esophageal involvement as an initial manifestation of Churg-Strauss syndrome
    Olivier Mir
    Service de Medecine Interne, centre de référence maladies rares, Hopital Cochin, AP HP, Universite Paris Descartes, Paris
    Presse Med 36:57-60. 2007
    ..Churg-Strauss syndrome (CSS) is a systemic disease characterized by asthma, blood and tissue eosinophilia, and necrotizing vasculitis with extravascular eosinophilic granulomas...
  89. ncbi request reprint Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated
    Christian Pagnoux
    Hopital Cochin, Service de Medecine Interne, 27, rue du Faubourg Saint Jacques, Paris Cedex 14, France
    Medicine (Baltimore) 84:115-28. 2005
    ....
  90. ncbi request reprint [Neuropsychiatric manifestations in systemic sclerosis]
    David Launay
    Universite Lille 2, Service de Medecine Interne, Centre de référence de la sclérodermie systémique, Hopital Claude Huriez, CHRU Lille, F 59037 Lille Cedex, France
    Presse Med 39:539-47. 2010
    ..If morphological CNS abnormalities could be linked to neuropsychiatric manifestations, it would be possible to identify neuropsychiatric scleroderma as we can now identify neuropsychiatric systemic lupus erythematosus...
  91. ncbi request reprint Pathogenic effects of antimyeloperoxidase antibodies in patients with microscopic polyangiitis
    Philippe Guilpain
    Universite Paris Descartes, Hopital Cochin, Assistance Publique Hopitaux de Paris, Paris, France
    Arthritis Rheum 56:2455-63. 2007
    ..The aim of this study was to investigate whether anti-MPO antibodies can activate MPO to generate an oxidative stress that is potentially deleterious to the endothelium...